Instil Bio, Inc. — 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone fourth-quarter report. Instil Bio is a clinical-stage biopharmaceutical company developing autologous tumor-infiltrating lymphocyte (TIL) cancer therapies. It had no approved products and generated no product revenue.
Financial performance and position
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $141.1 million | $107.3 million |
| General and administrative expense | $62.2 million | $48.3 million |
| Restructuring and impairment charges | $23.2 million | None |
| Total operating expenses | $226.5 million | $155.6 million |
| Net loss | $223.2 million | $156.8 million |
| Net loss per share, basic and diluted | $1.72 | $1.48 |
| Cash used in operating activities | $180.2 million | $122.1 million |
| Cash, cash equivalents and marketable securities at year-end | $260.9 million | $454.1 million |
At December 31, 2022, current assets were $269.4 million and current liabilities were $32.8 million. The company reported $74.8 million of construction-loan principal outstanding ($72.4 million net of unamortized issuance costs), secured by its Tarzana, California property. The loan matures in July 2025, with an option to extend to July 2027; it carries a variable rate and financial covenants. Stockholders’ equity was $363.6 million. No operating margin is meaningful because the company had no product revenue.
Material changes and unusual items
- Net loss increased by $66.4 million year over year. Operating expenses rose $70.9 million, reflecting higher R&D and G&A spending and $23.2 million of restructuring and impairment charges.
- The 2022 charges included $15.8 million of goodwill and in-process R&D impairments, $1.9 million of other asset impairments, $3.0 million of employee termination costs and $2.4 million of contract terminations.
- Operating cash use increased $58.0 million year over year. Investing activities provided $114.5 million, mainly because marketable securities matured; financing activities provided $71.9 million, principally from the construction loan.
- Marketable securities declined to $217.2 million from $416.5 million. Property, plant and equipment increased to $196.9 million, including substantial construction in progress for the Tarzana facility.
Business, outlook and key risks
- Pipeline focus: The FDA cleared the IND for ITIL-306 in May 2022. The Phase 1 dose-escalation study targets non-small cell lung, ovarian and renal cancers; the first patient was dosed in October 2022. Management expected initial clinical data in 2024 and planned a UK trial, subject to MHRA filings.
- Strategic reprioritization: In December 2022, the company discontinued ITIL-168 and redirected resources to ITIL-306, CoStAR and next-generation TIL technologies. The company reported pausing enrollment in 2022 after manufacturing problems; it said an investigation identified a central contamination source in cell media and that corrective actions were taken. It cautioned that these actions may not prevent further problems.
- Restructuring and facilities: A January 2023 expansion of the restructuring was expected to reduce the U.S. team to about 15 and leave about 65 UK employees, with implementation substantially complete by the end of April 2023. The company estimated up to $9.0 million in additional restructuring charges. It was evaluating a sale or lease of the Tarzana facility and subleases of other leased space.
- Liquidity outlook: Management stated that the revised operating plan was expected to fund operations beyond 2026. However, another part of the filing estimated funding into 2025. Both estimates depend on assumptions, including successful cost reductions and facility transactions; additional capital may be needed.
- Principal risks: Clinical and regulatory uncertainty; cell-therapy manufacturing reliability and supply constraints; competition; future financing needs; and the ability to execute the UK-centered operating plan. In January 2023, Nasdaq notified the company that its share price did not meet the $1.00 minimum bid-price requirement.
The company reported no material legal proceedings. Its auditor issued an unqualified opinion on the financial statements; the auditor did not attest to internal control over financial reporting.
Important facts for investors to verify
- Whether ITIL-306 enrollment, manufacturing success and trial timing support the anticipated 2024 data update.
- Whether the manufacturing corrective actions resolved the contamination and other production issues, and whether any new trial delays occurred.
- Which cash-runway estimate is current—into 2025 or beyond 2026—and the assumptions underlying it.
- Progress and financial consequences of the workforce restructuring, Tarzana facility sale or lease, and other planned subleases.
- Construction-loan balance, interest-rate exposure, covenant compliance and extension terms, as well as Nasdaq bid-price compliance.